Implications for Canada

U.S. Most-Favored-Nation (MFN) pricing proposals are creating uncertainty for pharmaceutical manufacturers, with potential implications beyond the U.S. The presentation will explore implications for established medicines and new launches, including launch timing, market availability, and commercial partnerships.  Take back to your team a blueprint to help you: 

• Assess key risks and signals Canadian stakeholders should monitor as international pricing policy evolves. 
• Understand the dynamics at play internationally that may influence access and launch decisions 
• Develop a strategy to navigate potential impact on pricing 

Identify the implications for your launch sequencing, price sustainability, and navigating increasing cross-market dependencies